Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial.

Ann Rheum Dis · 2015 · PMC4431334 · PMID 24550168

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

See: http://creativecommons.org/licenses/by-nc/3.0/ Objective CONCERTO was a randomised, double-blind, parallel-armed study of methotrexate (MTX) in combination with adalimumab to assess whether an increasing trend of efficacy and decreased safety exists when increasing MTX dose in patients with early rheumatoid arthritis (RA).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.